Bristol Myers Squibb’s Post

We have been recognized by S&P Global’s Dow Jones Sustainability Index North America as a corporate sustainability industry leader. This accomplishment reflects our commitment to continuously improving our environmental, social and governance practices to creating a sustainable around the world. Learn more about our commitment to operating responsibly: https://bit.ly/3W1c5Ip #DJSI #sustainability #ESG

Sixty of our colleagues in Australia, China, Japan, Korea, Taiwan and the United States begin their #C2C4C Japan fundraising this month, culminating in an epic bike ride this October. Learn about their journey as they raise funds for CancerNet Japan to advance cancer research for patients. See more: https://bit.ly/4cjOw3o

We’ve advanced LGBTQIA+ inclusion in over a dozen U.S. clinical trials since last year by implementing orientation, gender identity, and intersex status (SOGIIS) data. This #PrideMonth, learn about our efforts to do more across the industry to expand clinical trial diversity while respecting patients’ privacy: https://bit.ly/4cjtkuf

We are thrilled to announce that Francisco Ramírez-Valle, MD, PhD, FAAD, our Senior Vice President and Head of the Immunology and Cardiovascular Thematic Research Center, has been recognized in Endpoints News' annual feature on LGBTQ+ leaders in biopharma! Francisco's leadership and dedication to advancing scientific research while fostering an inclusive environment exemplify our core values at Bristol Myers Squibb. His contributions are not only shaping the future of the immunology and cardiovascular treatment landscape but also paving the way for greater LGBTQ+ representation in clinical trials and the biotech industry overall. “If I can be a mentor to anyone, whether they’re a Latino kid...or from a sexual minority, that they can achieve everything that they want and become a leader if that’s what they want, that would be amazing,” he said. While we celebrate Francisco and the other incredible honorees, we must acknowledge the challenges the LGBTQ+ community continues to face. Francisco's recognition is a testament to the progress we've made and the work that still needs to be done. Join us in celebrating Francisco and the inspiring work of all the honorees. #LGBTQLeadership #SOGIIS #HealthEquity Read more: https://bit.ly/3ztX354

Our team is consistently pursuing innovative research and solutions to help people living with immune-mediated diseases like #UlcerativeColitis find relief. Learn more about an exciting new analysis of our Phase 3 trial evaluating a treatment for adults with moderately-to-severely active ulcerative colitis. Read more in the journal Clinical Gastroenterology and Hepatology. https://bit.ly/4eA8qIP

Reflecting cancer's complexities and courageously pushing boundaries, our research framework helps us advance transformative therapies for patients. See how we're shifting the R&D industry mindset: https://bit.ly/3zhENff

Our scientists leverage #AI and #MachineLearning to build on our 20-year legacy in #ProteinDegradation and advance our research. In our latest #DecodedByBMS article, Neil Bence and Kai Wang reveal how we’re leveraging cutting-edge technologies to accelerate target identification and degrader discovery, design and development. 

We're passionate about transforming cardiovascular care worldwide, which is why we’re working with global patient advocacy organizations like Global Heart Hub, The Mended Hearts, Inc., Mended Hearts Europe, Hypertrophic Cardiomyopathy Association and Instituto Lado a Lado pela Vida, who share our mission of creating a world with better outcomes for those living with #cardiovascular diseases. Together, we can better support patients with conditions like #hypertrophiccardiomyopathy (HCM). Learn more: https://bit.ly/3xjFrIM